National Health (Ceasing of Co-marketed Brands) Determination 2013 (No. 1) (No. PB 20 of 2013) (Australia)

National Health (Ceasing of Co-marketed Brands) Determination 2013 (No. 1) (No. PB 20 of 2013)

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Unlimited Searches
Weekly Updates on New Laws
Access to 5,345,848 Global Laws from 110 Countries
View the Original Law Side-by-Side with the Translation

Subscribe Now for only USD$40 per month.

PB 20 of 2013

National Health (Ceasing of Co-marketed Brands) Determination 2013 (No. 1)1

National Health Act 1953
___________________________________________________________________________

I, ADRIANA PLATONA, Assistant Secretary, Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, determine under subsection 84AE(3B) of the National Health Act 1953 (“the Act”) that the brands of pharmaceutical items specified in columns 2 and 3 of an item specified in column 1 of the Schedule cease to be co-marketed brands of a pharmaceutical item.

This instrument commences on 1 April 2013;

Dated 27 March 2013

ADRIANA PLATONA
Assistant Secretary
Pharmaceutical Evaluation Branch
Pharmaceutical Benefits Division
Department of Health and Ageing

Schedule

Column 1
Column 2
Column 3

Item
Listed brand of pharmaceutical item
Listed brand of pharmaceutical item

Brand
Drug
Form
Manner of administration
Brand
Drug
Form
Manner of administration

1
Avapro
Irbesartan
Tablet 75 mg
Oral
Karvea
Irbesartan
Tablet 75 mg
Oral

2
Avapro
Irbesartan
Tablet 150 mg
Oral
Karvea
Irbesartan
Tablet 150 mg
Oral

3
Avapro
Irbesartan
Tablet 300 mg
Oral
Karvea
Irbesartan
Tablet 300 mg
Oral

Note
1. All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See http://www.comlaw.gov.au.